GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer
Metrics: PDF 1322 views | HTML 1343 views | ?
Kunli Zhu1, Qianqian Zhao1,2, Jinbo Yue1, Pengyue Shi1, Hongjiang Yan1, Xiaoqing Xu1, Renben Wang1
1Department of Radiation Oncology, Shandong Cancer Hospital, Affiliated to Shandong University, Jinan, China
2School of Medicine and Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, China
Renben Wang, email: email@example.com
Keywords: GOLPH3, neoadjuvant chemoradiotherapy, rectal cancer, tumor response, survival
Received: July 10, 2016 Accepted: September 07, 2016 Published: September 13, 2016
Neoadjuvant chemoradiotherapy (nCRT) combined with surgery is a standard therapy for locally advanced rectal cancer (LARC). The aim of this study was to assess the expression of GOLPH3 (Golgi phosphoprotein 3), a newly found oncogene, in LARC as well as its relationship with nCRT sensitivity and prognosis. We retrospectively analyzed 148 LARC cases receiving nCRT and total mesorectal excision (TME). Immunohistochemistry was used to assess GOLPH3 and mTOR (mammalian target of rapamycin) in tumor tissues. Then, the associations of GOLPH3 with pathological characteristics and prognosis of rectal cancer were assessed. The 148 cases included 77 with high GOLPH3 expression (52.03%), which was associated with tumor invasive depth and lymphatic metastasis. Cases with high GOLPH3 expression had 2.58 and 2.71 fold higher local relapse and distant metastasis rates compared with the low expression group. Correlation analyses showed that GOLPH3 was an independent indicator for judging tumor down-staging and postoperative TRG (tumor regression grade), indicating it could predict nCRT sensitivity. In addition, GOLPH3 expression was associated with mTOR levels. Multiple-factor analysis indicated that GOLPH3 was an independent prognosis indicator for 5 year-DFS (disease free survival) and OS (overall survival) in LARC. These results reveal that GOLPH3 is an independent predictive factor for nCRT sensitivity and prognosis in LARC, with a mechanism related to mTOR.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.